Erythema - 149 Studies Found

Recruiting : A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC
: Stage IV Non-Small Cell Lung Cancer
: 2016-01-14
:
  • Drug: Pembrolizumab 200mg Pemb
Not yet recruiting : Discerning Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Guided Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
:
  • Prostate Cancer
  • Magnetic Resonance Imaging
  • Device: MRI/ultrasound transperineal fusion-guided prostate biopsy

Completed : Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
: Head and Neck Cancer
: 2001-08-10
: Drug: liposomal lurtotecan
Active, not recruiting : Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis (Dialysis Fistulae)
:
  • Vascular Access Complication
  • Restenosis, Vascular Graft
  • Di
    : 2017-01-19
    :
    • Device: Conventional angioplasty

Recruiting : HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction
:
  • Stevens-Johnson Syndrome
  • Kidney Failure, Chronic

: 2017-02-06
: Genetic: HLA-B*5801 test Check whether a participant has HLA-B*5801 allele or not, before administration
Not yet recruiting : Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
:
  • Stevens-Johnson Syndrome
  • Toxic Epidermal Necrolyses

: 2016-11-25
:
  • Drug: cyclosporin A Other Name
Completed : Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.
:
  • Stevens-Johnson Syndrome
  • Toxic Epidermal Necrolysis

: 2012-09-20
: Drug: Intravenous immunoglobulin
Completed : Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye
: Stevens-Johnson Syndrome
: 2010-11-08
: Drug: 0.05%cyclosporin eye drop use twice daily for 6 months
Withdrawn : Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
:
  • Stevens-Johnson Syndrome
  • Corneal Blindness

: 2010-11-19
: Drug: Infliximab The drug will be administered intravenously every month for 110 weeks (duration of the
Completed : Salivary Gland Transplantation in the Treatment of Dry Eye in Patients With Stevens-Johnson Syndrome.
:
  • Symblepharon
  • Dry Eye
  • Ocular Surface Disease
  • : 2010-01-19
    : Procedure: Salivary Gland and Labial Mucous Membrane Transplantation Minor salivary glands (SG) will be
<<< Previous | Next >>>